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Nosocomial infections caused by carbapenem-resistant Acinetobacter baumannii isolates
have  reached epidemic levels in past decades. Currently this microorganism is responsi-
ble for outbreaks of difﬁcult eradication and with high mortality rates worldwide. We  herein
report a rare case of an OXA-72-producing A. baumannii isolate colonizing a 47-year-old
male patient with peritonitis due to abdominal stab wound, four years earlier than the ﬁrst
report of this carbapenemase in Acinetobacter pittii in Colombia. Although OXA-72 presents
a  low prevalence compared with OXA-23, our study demonstrated that A. baumannii iso-
lates carrying the blaOXA-72 gene were present in the hospital environment in Colombia andOxacillinase
Colombia
could act as a reservoir for further spread to other Acinetobacter species, like A. pittii, causing
carbapenem-resistance.
©  2014 Elsevier Editora Ltda. All rights reserved.Introduction
Carbapenem-resistant Acinetobacter baumannii became a
1global health concern, especially in intensive care units
(ICUs).2 In Colombia, A. baumannii was the ﬁfth most fre-
quent pathogen causing bloodstream infections between the
years 2001 and 2008 at ICUs, with an increased of 40% in the
∗ Corresponding author at: Laboratório ALERTA, Universidade Federal 
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E-mail address: rodrigocayosilva@gmail.com (R. Cayô).
http://dx.doi.org/10.1016/j.bjid.2014.05.017
1413-8670/© 2014 Elsevier Editora Ltda. All rights reserved.carbapenem resistance.3 This fact could partially be explained
by the spread of OXA-23-producing clones in Colombian
hospitals.4 Montealegre and colleagues5 reported, for the ﬁrst
time in Colombia, an OXA-72-producing Acinetobacter pittii iso-
lated in 2010 from a catheter tip culture. Here, we describede São Paulo – UNIFESP, Rua Pedro de Toledo, 781, 6th ﬂoor, Vila
a case of OXA-72-producing A. baumannii strain colonizing a
patient with peritonitis in Colombia, four years earlier than
the ﬁrst reported case.5
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ase  presentation
n January 20, 2006, a 47-year-old male patient was hos-
italized at a tertiary teaching hospital localized in Bogota,
olombia, due to an abdominal stab wound. The patient was
ubmitted to exploratory laparotomy and a segmental small
owel resection was performed. Antimicrobial therapy with
lindamycin (600 mg  iv q8 h) and amikacin (1 g iv q24 h) was
dministered for seven days, and the patient was discharged
n good clinical conditions eight days later. On February 2,
006, the patient was readmitted due to severe abdominal
ain and a new exploratory laparotomy was carried out.
eritonitis was diagnosed secondary to a small bowel per-
oration. Peritoneal ﬂuid culture was not performed at that
ime. Antimicrobial therapy with ampicillin/sulbactam (3 g iv
6 h) was empirically prescribed and maintained for eight days
ith clinical improvement. However, on February 9, 2006, the
atient presented with vomit, severe abdominal pain, fever
nd leukocytosis. Another exploratory laparotomy was car-
ied out and the presence of multiple intestinal perforations
as diagnosed. The antimicrobial therapy was replaced by
eropenem (2 g iv q8 h) and the patient was then transferred
o the ICU, where he remained for the next six days. The
bdominal incision had been left completely open and subse-
uently intra-abdominal lavages were performed. In the two
revious peritoneal lavages, the cultures were negative. On
ebruary 16, 2006, after the third peritoneal lavage, the perit-
neal cavity was closed and the patient was transferred to the
nternal medicine ward. At this moment, a non-fermenting
ram-negative coccobacillus isolate (Acb7-31 strain) was cul-
ured from the peritoneal ﬂuid. It was initially identiﬁed as
 carbapenem-resistant A. baumannii by VITEK 2 automated
ystem (bioMérieux SA, Marcy  l’Etoile, France). The patient
as discharged at 23rd day of hospitalization in good clinical
onditions.
Species identiﬁcation by sequencing analysis of RNA poly-
erase  subunit (rpoB) gene, as previously published,6
onﬁrmed the identiﬁcation of Acb7-31 strain as A. bau-
annii. Antimicrobial susceptibility was evaluated by CLSI
roth microdilution,7 except for amikacin and colistin MICs
hat were determined by Etest strips, according to the
anufacturer’s recommendations (AB Biodisk, Solna, Swe-
en). According to CLSI breakpoints,8 the Acb7-31isolate was
usceptible to minocycline (MIC, ≤0.03 mg/L), ciproﬂoxacin
MIC, ≤0.125 mg/L), colistin (MIC, 0.5 mg/L), polymyxin B
MIC, 0.5 mg/L), amikacin (MIC, 2 mg/L), gentamicin (MIC,
 mg/L), ceftazidime (MIC, 8 mg/L), cefotaxime (MIC, 8 mg/L),
ntermediate to levoﬂoxacin (MIC, 4 mg/L) and resistant
o imipenem (MIC, 32 mg/L), meropenem (MIC, 32 mg/L),
mpicillin-sulbactam (MIC, 32/16 mg/L) and cefepime (MIC,
4 mg/L). In order to evaluate the contribution of overex-
ression of efﬂux pumps in the resistance to carbapenems,
he MICs for imipenem and meropenem were also deter-
ined in the presence of 15 mg/L of the efﬂux pump
nhibitor, Phe-Arg--naphthylamide (PAN). Although a 4-
old decrease in the MICs for meropenem was observed
n the presence of PAN (MICs, 32 to 8 mg/L), the MICs
or imipenem did not change signiﬁcantly (MICs, 32 to
6 mg/L).4;1 8(6):678–680 679
Multiplex-PCR assays targeting carbapenem-hydrolyzing
class D -lactamases (CHDLs) and metallo--lactamase (MLs)
encoding genes were performed, as previously published.9,10
The presence of blaOXA-51-like and blaOXA-24/40-like was con-
ﬁrmed by PCR. DNA sequencing identiﬁed the blaOXA-24/40-like
amplicon as blaOXA-72 and revealed that it was ﬂanked
by XerC/XerD-binding sites, a structure implicated with its
mobilization.11 Genomic DNA digested with the endonuclease
I-Ceu-I and plasmid DNA from Acb7-31 strain were separated
by PFGE, and subsequent Southern blot and hybridization
with blaOXA-72-speciﬁc probe showed that the blaOXA-72 gene
was located on a plasmid of ∼20 kb. It seems that this is a
non-conjugative plasmid since it was not successfully trans-
ferred by conjugation. Similar results were observed by Bonnin
and colleagues12 who described three French A. pittii isolates
carrying the blaOXA-72 gene mediated by a non conjugative
20-kb plasmid. Interesting, the sizes of plasmids carrying the
blaOXA-72 gene in Acinetobacter spp. isolates varies considerably
in South America, ranging from 83 kb to 163 kb, as previously
reported.5,13,14
Conclusion
Despite its lower prevalence, OXA-72 had been present in
Colombia longer than we thought, since the Acb7-31 strain
was isolated in 2006 in Bogota, located 462.4 km from Cali,
where an OXA-72-producing A. pittii strain was isolated in
2010. Although the Acb7-31 strain was considered as a colo-
nizer strain, our study documented that blaOXA-72 was present
in the hospital environment and could act as a reservoir
for further spread to other Acinetobacter species, like A. pit-
tii.  In addition, the overexpression of efﬂux pumps seems to
contribute for increasing meropenem MICs for inhibiting the
Acb7-31 strain.
Funding
This study was ﬁnanced by Colciencias CODE: 11010416355,
Agreement 444 and Universidad Nacional de Colombia CODE:
20201009713.
Conﬂicts  of  interests
A.C.G. recently received research funding and/or consultation
fees from AstraZeneca and Thermo Fisher Scientiﬁc. Other
authors have nothing to declare.
Acknowledgements
GREBO (Andrés González), Clínica de Occidente (Elkin Lemus,
Norma Montoya, Marta Salinas, Francelina González, Edgar
Sánchez), Clínica Jorge Pin˜eros Corpas (Geny Díaz, Carlos
Barrios), Clínica Reina Sofía (Edilma Torrado, Diego Garzón),
Clínica San Pedro Claver (Carlos Alquichire, Marta Ruiz, Gladis
Ceballos, Pilar Hurtado, Jose Guillermo Ruiz Rodríguez), Fun-
dación Cardioinfantil (Álvaro Arango, Patricia Bravo), Hospital
Occidente de Kennedy (Romelia Villa, Nubia Escobar, Piedad
Giraldo, Álvaro Jiménez), Hospital El Tunal (Marta Isabel
i s . 2 0
r
1
1
1
1
1680  b r a z j i n f e c t d 
Garzón, Julia Quijano, Rafael Pérez Yepes), Hospital Militar
Central (Carlos Pérez, Matilde Méndez, María Nilse González,
Diana Ferrucho, Juan Pablo Velásquez), Hospital Universitario
San Ignacio (Carlos Álvarez, Beatriz Ariza), Hospital Simón
Bolívar (Constanza Correa, Luz Janeth Márquez, William Clav-
ijo), Hospital Santa Clara (José Roberto Tamara, Gloria Inés
Gallo, Guillermo Ortiz), Hospital Universitario Clínica San
Rafael (Marta Pulido, Rabel Lobelo), Hospital Universitario La
Samaritana (Johana Osorio, Elsa Marina Zubieta, Emilio Rey),
Instituto Nacional de Cancerología (Jorge Cortes, Claudia Patri-
cia Arroyo, Luz Marina Martínez, Elizabeth Rodríguez, Clara
Inés Gómez), Policlínico del Olaya (Johana Carol Estrada, Ana
Isabel Sánchez, Carlos Hurtado Hurtado).
 e  f  e  r  e  n  c  e  s
1. Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant
Acinetobacter baumannii: epidemiology, surveillance and
management. Expert Rev Anti Infect Ther. 2013;11:
383–93.
2. Ogutlu A, Guclu E, Karabay O, Utku AC, Tuna N, Yahyaoglu M.
Effects of carbapenem consumption on the prevalence of
Acinetobacter infection in intensive care unit patients. Ann
Clin Microbiol Antimicrob. 2014;13:7.
3. Cortes JA, Leal AL, Montan˜ez AM, Buitrago G, Castillo JS,
Guzman L, GREBO. Frequency of microorganisms isolated in
patients with bacteremia in intensive care units in Colombia
and  their resistance proﬁles. Braz J Infect Dis. 2013;17:
346–52.4. Villegas MV, Kattan JN, Correa A, et al. Dissemination of
Acinetobacter baumannii clones with OXA-23 Carbapenemase
in Colombian hospitals. Antimicrob Agents Chemother.
2007;51:2001–4. 1 4;1  8(6):678–680
5. Montealegre MC, Maya JJ, Correa A, et al. First identiﬁcation of
OXA-72 carbapenemase from Acinetobacter pittii in Colombia.
Antimicrob Agents Chemother. 2012;56:3996–8.
6. La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the
rpoB gene and ﬂanking spacers for molecular identiﬁcation of
Acinetobacter species. J Clin Microbiol. 2006;44:827–32.
7. Clinical Laboratory Standard Institute. Methods for dilution
antimicrobial susceptibility test for bacteria that grow
aerobically – Ninth edition: Approved Standard M7-A9.
Wayne,  PA, USA: CLSI; 2012.
8. Clinical Laboratory Standard Institute. Performance
Standards for antimicrobial susceptibility testing –
Twenty-Third edition. Informational Supplement M100-S23.
Wayne,  PA, USA: CLSI; 2013.
9. Woodford N, Ellington MJ, Coelho JM, et al. Multiplex PCR for
genes encoding prevalent OXA carbapenemases in
Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–3.
0. Mendes RE, Kiyota KA, Monteiro J, et al. Rapid detection and
identiﬁcation of metallo-beta-lactamase-encoding genes by
multiplex real-time PCR assay and melt curve analysis. J Clin
Microbiol. 2007;45:544–7.
1. Merino M, Acosta J, Poza M, et al. OXA-24 carbapenemase
gene ﬂanked by XerC/XerD-like recombination sites in
different plasmids from different Acinetobacter species
isolated during a nosocomial outbreak. Antimicrob Agents
Chemother. 2010;54:2724–7.
2. Bonnin RA, Docobo-Pérez F, Poirel L, Villegas MV, Nordmann P.
Emergence of OXA-72-producing Acinetobacter pittii clinical
isolates. Int J Antimicrob Agents. 2014;43:195–6.
3. Werneck JS, Picão RC, Carvalhaes CG, Cardoso JP, Gales AC.
OXA-72-producing Acinetobacter baumannii in Brazil: a case
report. J Antimicrob Chemother. 2011;66:452–4.
4. de Sá Cavalcanti FL, Almeida AC, Vilela MA, de Morais Junior
MA, de Morais MM, Leal-Balbino TC. Emergence of
extensively drug-resistant OXA-72-producing Acinetobacter
baumannii in Recife, Brazil: risk of clonal dissemination. Diagn
Microbiol Infect Dis. 2013;77:250–1.
